Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R) 27-Apr-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R) Notice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until 2036

Geneva, Switzerland, April 27, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA ("APR"), has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Application No. 15/303,121 entitled, "Modified Release Orally Administered Amino Acid Formulations."

The allowed claims cover certain PKU GOLIKE(R) formulations in APR's product line, intended to enhance the dietary management of patients living with phenylketonuria (PKU). The PKU GOLIKE(R) family of products are a phenylalanine-free food for special medical purposes (FSMP), comprising amino acid granules engineered with APR's Physiomimic Technology(TM), a modified-release amino acid technology that ensures a prolonged physiological absorption of the amino acids, while also masking their unpleasant taste, odor and aftertaste.

The USPTO issues a patent Notice of Allowance after it determines a patent should be granted upon completion of any outstanding administrative requirements. The patent resulting from this application will have an expiration date of no earlier than September 27, 2036. When issued, the patent will supplement APR's PKU GOLIKE(R) intellectual property portfolio, which currently includes U.S. Patent No. 10,500,180, which also expires no earlier than September 27, 2036.